Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
Late last month, Bristol Myers Squibb's (NYSE: BMY) immunology drug, Sotyktu, received good news. The medicine was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adult patients with moderate to severe plaque psoriasis.
With an approval from the European Commission likely just months away, it's worth asking the following question: How much revenue could a plaque psoriasis indication in the European Union (E.U.) generate for the pharmaceutical company? Let's turn our attention to Sotyktu's phase 3 clinical trial results and the E.U. plaque psoriasis market to learn more.
Psoriasis is a common skin condition. Plaque psoriasis makes up between 80% and 90% of psoriasis cases. Plaques are raised red patches of skin that typically affect the elbows, knees, and scalp, but can show up anywhere. These areas of skin generally itch or hurt.
Source Fool.com
